Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Epidarex Capital is a transatlantic venture capital firm founded to invest in early-stage, high-growth life science and health technology companies. Established in both Bethesda, Maryland, USA, and Edinburgh, Scotland, the firm focuses on building companies in emerging and under-ventured research hubs within the UK and US. Epidarex Capital leverages its scientific and industry networks to create value and support the development of innovative healthcare solutions.
The firm has a strong presence in both North America and Europe, indicating a broad geographic reach. Epidarex Capital has recently closed Fund IV, securing $145 million to support the next wave of life science start-ups. This financial backing enhances their ability to invest in transformative innovations that address critical healthcare challenges.
Notable milestones include their active collaboration with leading universities and research institutions, which allows them to identify and develop promising technologies. Epidarex Capital's commitment to early-stage investments positions them as a key player in the life sciences sector.
Epidarex Capital invests in early-stage life science opportunities, particularly in biotechnology, pharmaceuticals, medical devices, and health technology. The firm typically provides seed or Series A funding to spin out innovations from leading medical research universities and institutions. Their investment strategy emphasizes transformative technologies that address significant unmet medical needs.
Key evaluation criteria include disruptive technologies with sustainable competitive advantages, robust intellectual property, and early traction from key opinion leaders. Epidarex Capital targets emerging research hubs in the US and UK, often collaborating with academic institutions to identify and develop innovative products for the global healthcare market.
Epidarex Capital has a diverse portfolio of notable companies, including:
A. Sinclair Dunlop - Managing Partner, with extensive experience in venture capital and life sciences.
Kyparissia Sirinakis - Managing Partner, specializing in early-stage investments in biotech and healthcare.
Elizabeth Roper, Ph.D. - Managing Partner, with a background in scientific research and investment.
Peter Finan, Ph.D. - Managing Partner, focusing on life sciences and technology commercialization.
Mary Canning, Ph.D. - Partner, experienced in biotech investments and strategic development.
Lori Krim Gough, Ph.D. - Partner, with expertise in healthcare and venture capital.
Henning Steinhagen, Ph.D. - Venture Partner, specializing in drug development and commercialization.
Anthony Voveris - Vice President of Finance, overseeing financial operations.
Matthew Miessau - Principal, involved in sourcing and evaluating investment opportunities.
Victor Pong, Ph.D. - Associate, focusing on due diligence and market analysis.
Melissa Lezameta, Ph.D. - Associate, with a background in life sciences and investment.
Bridget Harris - Director of Operations, managing operational aspects of the firm.
Alvin Lewis - Staff Accountant, handling financial reporting and compliance.
Megan MacDougall - Executive Assistant, supporting the team with administrative tasks.
To pitch to Epidarex Capital, founders should send an email to info@epidarex.com. It is important to include a comprehensive deck that outlines the business model, technology, market opportunity, and team background. Response times may vary, but founders can expect to hear back within a few weeks.
Epidarex Capital has established **Epidarex Exeed**, a therapeutic discovery engine aimed at advancing early-stage life science assets. Exeed focuses on transforming breakthrough innovations into investable assets over a 12-18 month period. This program is designed to support startups in navigating the complexities of bringing new therapies to market.
In recent months, Epidarex Capital has announced several significant developments within its portfolio. Lario Therapeutics received $2.4 million from The Michael J. Fox Foundation to advance its precision medicines for neurological disorders. Additionally, Harness Therapeutics has nominated a first-in-class drug candidate for Huntington’s Disease, marking a key milestone in its development.
Furthermore, Epidarex Capital announced the first close of Fund IV, securing $145 million to support the next wave of life science start-ups. This funding will enable the firm to continue its focus on transformative life science innovations and expand its portfolio in the biotech and health technology sectors.
What are Epidarex Capital's investment criteria?
Epidarex Capital focuses on early-stage life science opportunities, particularly in biotechnology, pharmaceuticals, medical devices, and health technology. They look for disruptive technologies that address unmet medical needs, sustainable competitive advantages, and robust intellectual property.
How can I apply or pitch to Epidarex Capital?
Founders can pitch to Epidarex Capital by sending an email to info@epidarex.com. It is advisable to include a detailed overview of the business, the technology, and the market opportunity in the pitch.
What makes Epidarex Capital different from other venture firms?
Epidarex Capital distinguishes itself through its strong connections with academic institutions and its focus on transformative life science innovations. Their transatlantic presence allows them to tap into emerging research hubs in both the US and UK.
What is the geographic scope of Epidarex Capital's investments?
The firm invests primarily in North America and Europe, targeting emerging research hubs in these regions.
What is the typical check size for investments?
Epidarex Capital typically provides seed or Series A funding, although specific check sizes may vary based on the opportunity and stage of the company.
What kind of post-investment involvement does Epidarex Capital have?
Epidarex Capital actively supports its portfolio companies through mentorship, operational support, and strategic guidance, leveraging their extensive network in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.